Biosyent Inc
XTSX:RX
Biosyent Inc
Operating Expenses
Biosyent Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biosyent Inc
XTSX:RX
|
Operating Expenses
-CA$21.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-13%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Operating Expenses
-$5.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Operating Expenses
-CA$126.8m
|
CAGR 3-Years
37%
|
CAGR 5-Years
30%
|
CAGR 10-Years
-26%
|
|
|
Cronos Group Inc
TSX:CRON
|
Operating Expenses
-$77.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-54%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Operating Expenses
-$151.2m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-123%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Operating Expenses
-CA$187.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-33%
|
|
Biosyent Inc
Glance View
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.
See Also
What is Biosyent Inc's Operating Expenses?
Operating Expenses
-21.8m
CAD
Based on the financial report for Sep 30, 2025, Biosyent Inc's Operating Expenses amounts to -21.8m CAD.
What is Biosyent Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-13%
Over the last year, the Operating Expenses growth was -14%. The average annual Operating Expenses growth rates for Biosyent Inc have been -14% over the past three years , -13% over the past five years , and -13% over the past ten years .
